Canada Pension Plan Investment Board Acquires Shares of 798,740 Edwards Lifesciences Corporation $EW

Canada Pension Plan Investment Board bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 798,740 shares of the medical research company’s stock, valued at approximately $72,254,000.

Several other large investors have also recently modified their holdings of EW. JPL Wealth Management LLC purchased a new position in Edwards Lifesciences in the 3rd quarter valued at approximately $25,000. Hanson & Doremus Investment Management purchased a new stake in shares of Edwards Lifesciences during the first quarter worth $25,000. MV Capital Management Inc. purchased a new stake in shares of Edwards Lifesciences during the fourth quarter worth $26,000. RMG Wealth Management LLC bought a new position in shares of Edwards Lifesciences in the first quarter worth $26,000. Finally, Kemnay Advisory Services Inc. bought a new position in shares of Edwards Lifesciences in the fourth quarter worth $27,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of NYSE EW opened at $89.97 on Friday. The stock’s 50-day moving average is $89.48 and its 200 day moving average is $84.99. The stock has a market cap of $51.81 billion, a price-to-earnings ratio of 51.71, a P/E/G ratio of 2.38 and a beta of 0.85. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $96.29. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The business had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. During the same quarter in the prior year, the firm earned $0.67 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, sell-side analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Wall Street Analyst Weigh In

EW has been the topic of a number of analyst reports. Evercore reiterated an “outperform” rating and set a $100.00 price objective on shares of Edwards Lifesciences in a research note on Monday, July 6th. Wall Street Zen downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Citigroup raised their target price on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Piper Sandler reaffirmed an “overweight” rating and set a $101.00 target price (up from $100.00) on shares of Edwards Lifesciences in a report on Friday, July 24th. Finally, BTIG Research upped their price target on Edwards Lifesciences from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. Seventeen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $100.27.

Insider Activity

In other news, VP Daniel J. Lippis sold 619 shares of the company’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the sale, the vice president owned 40,034 shares of the company’s stock, valued at approximately $3,684,329.02. This represents a 1.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 1,857 shares of company stock valued at $170,305. 0.31% of the stock is currently owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.